Abstract
Objective
Part of the beneficial effects of metformin on the prevention of cardiovascular events in diabetes can be attributed to pleiotropic effects, including a blood pressure (BP)-lowering effect. In a double-blind parallel clinical trial (NCT02072382), the effect of metformin on BP evaluated by ambulatory blood pressure monitoring (ABPM) was measured.
Methods
Ninety-seven patients with hypertension, but without diabetes mellitus, were randomized to receive 850–1700 mg of metformin (n = 48) or placebo (n = 49). Clinical, laboratory, and ABPM data were collected at the baseline and after 8 weeks of follow-up.
Results
The sample consisted mainly of White overweight women. There was no difference in BP reduction measured by ABPM between both groups. There was no effect in BP measured in the different periods of ABP monitoring and office BP. Additionally, fasting plasma glucose, lipids, and C-reactive protein remained unchanged during the trial. There was a significant reduction in waist circumference with metformin (95.1 ± 10.4 to 89.3 ± 27.4 cm; p = 0.02).
Conclusion
In the present trial, metformin did not reduce BP, measured by ABP monitoring, in hypertensive patients without diabetes.
http://bit.ly/2T28vOA
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου